Berghammer P, Pfeffel F, Winkelbauer F, Wiltschke C, Schenk T, Lammer J, Müller C, Zielinski C
Department of Internal Medicine I, University of Vienna Medical School, Austria.
Cardiovasc Intervent Radiol. 1998 May-Jun;21(3):214-8. doi: 10.1007/s002709900247.
A survival analysis in 16 patients with unresectable hepatocellular carcinoma (HCC) undergoing transcatheter arterial embolization (TAE) using a combination of lipiodol and N-butyl-2-cyanoacrylate (5:1) was performed in a retrospective study.
A combination of lipiodol and N-butyl-2-cyanoacrylate (5:1) was used for TAE. All patients had disease compatible with Okuda stages I and II.
Twenty-four embolizations were done; five patients had more than one embolization. Median alpha-fetoprotein levels declined from 116 to 48.6 ng/ml. A median of 0.3 ml cyanoacrylate was administered per patient. Median survival was 8.5 months (range 2-49 months). After a median follow-up of 4 years, 12 patients have died (75%). Okuda stage I and II patients had a median survival time of 34.4 and 5.5 months respectively. Few side effects (19%) were seen.
We conclude that the TAE procedure used [lipiodol and N-butyl-2-cyanoacrylate (5:1)] is safe and produced only few side effects, thus constituting a valuable therapeutic option for patients with Okuda stage I and II HCC.
在一项回顾性研究中，对16例无法切除的肝细胞癌（HCC）患者进行经导管动脉栓塞术（TAE），使用碘油和N-丁基-2-氰基丙烯酸酯（5:1）的组合进行生存分析。
使用碘油和N-丁基-2-氰基丙烯酸酯（5:1）的组合进行TAE。所有患者的疾病均符合奥田分期I期和II期。
共进行了24次栓塞；5例患者进行了不止一次栓塞。甲胎蛋白水平中位数从116降至48.6 ng/ml。每位患者使用的氰基丙烯酸酯中位数为0.3 ml。中位生存期为8.5个月（范围2-49个月）。中位随访4年后，12例患者死亡（75%）。奥田分期I期和II期患者的中位生存时间分别为34.4个月和5.5个月。观察到的副作用很少（19%）。
我们得出结论，所使用的TAE程序[碘油和N-丁基-2-氰基丙烯酸酯（5:1）]是安全的，仅产生很少的副作用，因此对于奥田分期I期和II期的HCC患者构成一种有价值的治疗选择。
Zotero 插件